162 related articles for article (PubMed ID: 37088982)
1. Behavioural activity pattern, genetic factors, and the risk of nonalcoholic fatty liver disease: A prospective study in the UK Biobank.
Ge X; Wang X; Yan Y; Zhang L; Yu C; Lu J; Xu X; Gao J; Liu M; Jiang T; Ke B; Song C
Liver Int; 2023 Jun; 43(6):1287-1297. PubMed ID: 37088982
[TBL] [Abstract][Full Text] [Related]
2. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
[TBL] [Abstract][Full Text] [Related]
3. Association between night shift work and NAFLD: a prospective analysis of 281,280 UK Biobank participants.
Huang H; Liu Z; Xie J; Xu C
BMC Public Health; 2023 Jul; 23(1):1282. PubMed ID: 37400787
[TBL] [Abstract][Full Text] [Related]
4. Intake of the different types of dairy products, genetic predisposition, and the risks of nonalcoholic fatty liver disease and cirrhosis: a prospective cohort study.
Wu H; Li S; Chen L; Xia Y; Tan X
Food Funct; 2024 May; 15(9):5050-5062. PubMed ID: 38656457
[No Abstract] [Full Text] [Related]
5. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
6. Physical activity and sedentary behavior can modulate the effect of the PNPLA3 variant on childhood NAFLD: a case-control study in a Chinese population.
Wang S; Song J; Shang X; Chawla N; Yang Y; Meng X; Wang H; Ma J
BMC Med Genet; 2016 Dec; 17(1):90. PubMed ID: 27905898
[TBL] [Abstract][Full Text] [Related]
7. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents.
Zusi C; Mantovani A; Olivieri F; Morandi A; Corradi M; Miraglia Del Giudice E; Dauriz M; Valenti L; Byrne CD; Targher G; Maffeis C
Dig Liver Dis; 2019 Nov; 51(11):1586-1592. PubMed ID: 31255630
[TBL] [Abstract][Full Text] [Related]
8. The sulfur microbial diet and risk of nonalcoholic fatty liver disease: a prospective gene-diet study from the UK Biobank.
Liu Z; Huang H; Ruan J; Wang Z; Xu C
Am J Clin Nutr; 2024 Feb; 119(2):417-424. PubMed ID: 38000660
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Lin YC; Chang PF; Chang MH; Ni YH
Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
[TBL] [Abstract][Full Text] [Related]
10. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
[TBL] [Abstract][Full Text] [Related]
11. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
Lee KJ; Moon JS; Kim NY; Ko JS
Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
14. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S; Pang J; Huang R; Xue H; Chen X
Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
[TBL] [Abstract][Full Text] [Related]
15. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
16. A healthy lifestyle, Life's Essential 8 scores and new-onset severe NAFLD: A prospective analysis in UK Biobank.
He P; Zhang Y; Ye Z; Li H; Liu M; Zhou C; Yang S; Gan X; Zhang Y; Qin X
Metabolism; 2023 Sep; 146():155643. PubMed ID: 37380018
[TBL] [Abstract][Full Text] [Related]
17. Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
Sharma D; Gotlieb N; Farkouh ME; Patel K; Xu W; Bhat M
J Am Heart Assoc; 2022 Jan; 11(1):e022576. PubMed ID: 34927450
[TBL] [Abstract][Full Text] [Related]
18. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China.
Chen LZ; Ding HY; Liu SS; Liu Q; Jiang XJ; Xin YN; Xuan SY
Lipids Health Dis; 2019 Feb; 18(1):45. PubMed ID: 30738435
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
[TBL] [Abstract][Full Text] [Related]
20. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
